IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tarsus”) today announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $125.0 million, before deducting placement agent fees and other private placement expenses..

加利福尼亚州尔湾，2026年8月6日（环球电讯社）——Tarsus Pharmaceuticals, Inc.（纳斯达克股票代码：TARS）（“Tarsus”）今日宣布，公司已与某些合格机构买家和认可投资者签订证券购买协议，进行一项私募股权投资（PIPE）融资，预计扣除配售代理费及其他私募费用前的总收益约为1.25亿美元。

The PIPE financing includes participation from existing investors of Alkeus Pharmaceuticals (“Alkeus”), including TCGX, Bain Capital Life Sciences, and Wellington Management. Tarsus announced the pending acquisition of Alkeus in a press release earlier today. The additional PIPE investors include new and existing Tarsus investors, including ADAR1 Capital Management, Sirenia Capital Management LP, RTW Investments, and Vestal Point Capital, among others..

此次PIPE融资包括Alkeus Pharmaceuticals（“Alkeus”）现有投资者的参与，其中包括TCGX、Bain Capital Life Sciences和Wellington Management。Tarsus在今天早些时候发布的一份新闻稿中宣布了对Alkeus的待完成收购。其他PIPE投资者还包括Tarsus的新老投资者，其中包括ADAR1 Capital Management、Sirenia Capital Management LP、RTW Investments和Vestal Point Capital等。

Pursuant to the terms of the securities purchase agreement, Tarsus is selling an aggregate of (i) 2,098,519 shares of its common stock (“Common Stock”) at a purchase price of $56.00 per share, and (ii) pre-funded warrants (“Pre-Funded Warrants”) to purchase 133,625 shares of common stock at a purchase price of $55.9999 per Pre-Funded Warrant.

根据证券购买协议的条款，Tarsus 正在出售合计 (i) 2,098,519 股其普通股（“普通股”），每股购买价格为 56.00 美元；以及 (ii) 预付认股权证（“预付认股权证”），用于以每份预付认股权证 55.9999 美元的购买价格购买 133,625 股普通股。

The Pre-Funded Warrants have an exercise price of $0.0001 per share. The PIPE financing is expected to close on August 7, 2026, subject to the satisfaction of customary closing conditions..

预融资认股权证的行权价格为每股0.0001美元。PIPE融资预计将于2026年8月7日完成，但须满足惯常的交割条件。

Tarsus intends to use the net proceeds from the PIPE financing to fund clinical development and commercial activities and for other general corporate purposes.

Tarsus 计划将私募股权投资（PIPE）融资的净收益用于资助临床开发和商业化活动，以及其他一般公司用途。

Barclays is acting as lead placement agent and BofA Securities and William Blair are acting as co-placement agents in the PIPE financing.

巴克莱银行担任牵头配售代理，美国银行证券和威廉·布莱尔公司担任联合配售代理，负责此次PIPE融资。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor a solicitation of any vote or approval with respect to the proposed transactions or otherwise, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售要约或购买要约的招揽，也不构成就拟议交易或其他事项征求任何投票或批准的行为；在任何州或其他司法管辖区，若在此类要约、招揽或销售根据该州或其他司法管辖区的证券法进行注册或资格认定之前属于违法行为，则不得在该州或其他司法管辖区销售这些证券。

The sales of securities of Tarsus described above are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction's securities laws and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and/or applicable state or other jurisdictions’ securities laws..

上述塔苏斯公司证券的销售是在不涉及公开发行的交易中进行的，且该等证券未根据经修订的《1933年证券法》（以下简称“《证券法》”）或任何州或其他适用司法管辖区的证券法律进行注册。除非依据有效的注册声明或符合《证券法》及/或适用州或其他司法管辖区证券法律规定的注册要求豁免，否则不得在美国再次发售或转售该等证券。

About Tarsus Pharmaceuticals, Inc.

关于Tarsus制药公司

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention.

Tarsus Pharmaceuticals, Inc. 运用经过验证的科学和新技术，从眼科护理开始，彻底改变患者的治疗方式。Tarsus 正在推进其研发管线，以应对多个治疗领域（包括眼科护理、皮肤科和传染病预防）中尚未得到充分满足的高需求疾病。

XDEMVY.

XDEMVY。

®

®

(lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of

（洛替拉纳滴眼液）0.25% 已获美国食品药品监督管理局（FDA）批准，用于治疗

Demodex

蠕形螨

blepharitis. Tarsus is also developing TP-04 for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, both of which are in Phase 2, and IRX-101 for potential use as an ocular antiseptic.

睑缘炎。Tarsus 公司也在开发 TP-04，用于潜在治疗眼玫瑰痤疮；开发 TP-05（口服片剂），用于潜在预防莱姆病；这两者均处于二期临床试验阶段。此外，该公司还在开发 IRX-101，用于潜在作为眼部抗菌剂。

Forward-Looking Statements

前瞻性陈述

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words.

本新闻稿中关于未来预期、计划和前景的陈述，以及任何其他非历史事实的陈述，可能构成“前瞻性陈述”。词语包括但不限于“相信”、“考虑”、“继续”、“可能”、“估计”、“预期”、“打算”、“可以”、“或许”、“计划”、“潜在”、“预测”、“规划”、“应当”、“目标”、“将”或“会”，或这些术语的否定形式或其他类似表达，旨在识别前瞻性陈述，尽管并非所有前瞻性陈述都包含这些或类似的识别词。

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, risks and uncertainties related to the satisfaction of customary closing conditions related to the PIPE financing. Further, there are other risks and uncertainties that could cause actual results to differ from those set forth in the forward-looking statement and they are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus’ Form 10-K for the year ended December 31, 2025, filed on February 23, 2026 with the SEC, and the most recent Form 10-Q quarterly filing filed on August 6, 2026 with the SEC, copies of which are posted on its website and are available from Tarsus without charge.

由于各种重要因素，包括但不限于与PIPE融资相关的惯例交割条件能否得到满足有关的风险和不确定性，实际结果可能与该等前瞻性陈述所指示的结果存在重大差异。此外，还有其他风险和不确定性可能导致实际结果与前瞻性陈述中列明的结果不同，这些因素在Tarsus向美国证券交易委员会（SEC）提交的报告中不时详细披露，包括Tarsus于2026年2月23日向SEC提交的截至2025年12月31日的年度Form 10-K报告，以及于2026年8月6日向SEC提交的最新Form 10-Q季度报告。这些报告的副本已发布在其网站上，并可向Tarsus免费索取。

However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus’ manageme.

然而，新的风险因素和不确定性可能不时出现，且无法预测所有的风险因素和不确定性。因此，提醒读者不要过度依赖这些前瞻性陈述。本新闻稿中包含的任何前瞻性陈述均基于Tarsus管理层的当前预期。

Media Contact:

媒体联系人：

Adrienne Kemp

阿德琳·肯普

Vice President, Corporate Communications

副总裁，企业传播

(949) 922-0801

(949) 922-0801

akemp@tarsusrx.com

akemp@tarsusrx.com

Investor Contact:

投资者联系：

David Nakasone

大卫·中曾根

Head of Investor Relations

投资者关系负责人

(949) 620-3223

(949) 620-3223

DNakasone@tarsusrx.com

DNakasone@tarsusrx.com